CURACHEM Co., ltd.
KKRX:4561907,210.00
KRW
-210.00
(-2.83%)
ISIN
KR7456190008
Return %
Stock
S&P 500
1Y
-9.87
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Suk-Jeong Shin
- Full Time Employees
- 29
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Cheongju-si South Korea
- IPO Date
- May 18, 2023
- Website
- curachem.com
- Similar Companies
- Business
- CURACHEM Co., ltd. is a South Korea-based contract research organization and specialized chemical synthesis company primarily engaged in the custom synthesis of radiolabeled and stable isotope-labeled compounds for pharmaceutical, biotechnology, and agrochemical research and development. Founded in 2009 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company provides critical scientific services supporting preclinical drug discovery, absorption, distribution, metabolism, and excretion (ADME) studies, toxicokinetics, and regulatory clinical pharmacology. The company operates through specialized service categories that include: Carbon-14 (14C) custom radiolabeling synthesis for small molecules and complex structures; Tritium (3H) radiolabeling services; stable isotope labeling (SIL) utilizing Deuterium (2H), Carbon-13 (13C), and Nitrogen-15 (15N) for bioanalytical internal standards; metabolite synthesis and reference standard preparation; radiolabeling of high-potency active pharmaceutical ingredients (HPAPIs); custom synthesis for emerging therapeutic modalities, including antibody-drug conjugates (ADCs), peptides, oligonucleotides, and targeted protein degraders (PROTACs); radio-analytical chemistry and characterization services utilizing high-performance liquid chromatography (HPLC) coupled with radio-detectors, liquid chromatography-mass spectrometry (LC-MS/MS), and nuclear magnetic resonance (NMR) spectroscopy; and radiochemical purity testing, storage stability assessment, and re-purification services. CURACHEM serves a diverse global customer base comprising multinational pharmaceutical corporations, clinical-stage biotechnology firms, academic research centers, and partner preclinical contract research organizations across South Korea, the United States, Europe, Japan, and the wider Asia-Pacific region. In recent corporate and operational developments, CURACHEM completed its public listing on the Korea Exchange (KRX: 456190) and has actively pursued strategic corporate positioning to broaden access to institutional capital. The company has expanded its laboratory infrastructure and synthetic capacity in Cheongju, enhancing its controlled radiochemical synthesis suites to accommodate high-potency compounds and expanding its portfolio into radiolabeled biologics and advanced conjugate therapeutics. Additionally, CURACHEM has strengthened its international footprint through new strategic business alliances and global service agreements with multinational preclinical research providers, accelerating cross-border project delivery and expanding its client network across North American and European pharmaceutical markets.